Marché mondial des tests de diagnostic rapide de la grippe (RIDT) – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse du marché et de la taille des tests de diagnostic rapide de la grippe (RIDT)

Selon les études de l'Organisation mondiale de la santé (OMS), la grippe saisonnière entraîne environ 3 à 5 millions de cas de maladie grave dans le monde chaque année. Le marché des tests de diagnostic rapide de la grippe (RIDT)  était évalué à environ 1 milliard USD en 2021. L'adoption croissante de nouvelles techniques de diagnostic de la grippe et le lancement de tests rapides de la grippe innovants par les principaux acteurs du marché créent des opportunités lucratives pour le marché.

Français Data Bridge Market Research analyse que le marché des tests de diagnostic rapide de la grippe (RIDT), qui était de 1 milliard USD en 2021, monterait en flèche pour atteindre 1,51 million USD d’ici 2029 et devrait connaître un TCAC de 5,25 % au cours de la période de prévision 2022 à 2029. En plus des informations sur le marché telles que la valeur du marché, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l’équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, l’épidémiologie des patients, l’analyse du pipeline, l’analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des tests de diagnostic rapide de la grippe (RIDT)  

Market Definition

Rapid diagnostic testing for influenza is a molecular assay that operates more rapidly than usual and provides high accuracy, high sensitivity, and high specificity. The simplicity of use, speed of results, high accuracy, and specificity of the results all contribute to the continued reliability of RIDT as a tool for influenza diagnostics, which explains the rise in its use in clinical decision-making for diagnosis and treatment. In the near future, a sizable number of diagnostic centres and laboratory testing units will also register substantial uptake, while hospitals are anticipated to remain the main client segment.

Rapid Influenza Diagnostic Tests (RIDTs) Market Dynamics

Drivers

• Rise in chronic diseases

In the forecast period of 2022–2029, a number of factors are expected to contribute to the growth of the market for rapid influenza diagnostic tests (RIDTs), including the increasing number of government initiatives taken to combat influenza outbreaks, the growing geriatric population worldwide, the advancement of advanced technology, and the rise in cardiovascular diseases and diabetes. The market for rapid influenza diagnostic tests (RIDTs) will expand over the aforementioned projected period as a result of increasing healthcare spending, rising research and development, and a number of other favourable factors.

• Rise in prevalence of influenza

The global market for rapid influenza diagnostic tests (RIDT) is anticipated to grow as influenza prevalence rises. The centers for disease control and prevention (CDC) predicts that influenza causes somewhere between 12,000 and 79,000 fatalities annually in the United States. The market is also anticipated to develop throughout the forecast period as awareness of the value of early identification and prevention of diseases like influenza increases.

Opportunities

• Increase in the number of research and development activities 

It is anticipated that increasing R&D spending will boost the global adoption rates of these diagnostic tests by providing technologically sophisticated solutions to identify influenza. The widespread use of quick influenza diagnostic testing and the rising influenza prevalence will drive the market revenue for these tests in the upcoming years.

Restraints/Challenges

• Unskilled professionals

On the other hand, the lack of skilled and professional personal along with unstable regulatory framework of new diagnostic test approval will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.

• Modern infrastructure in low-resource settings

However, the adoption of influenza testing in developing nations like India, China, and Mexico among others is hampered by the absence of skilled specialists and modern infrastructure in low-resource settings such as distant places, rural areas, and urban slums. Due to a lack of transportation and communication, access to high-quality healthcare is challenging to maintain in isolated and rural locations.

This rapid influenza diagnostic tests (RIDTs) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rapid influenza diagnostic tests (RIDTs) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Rapid Influenza Diagnostic Tests (RIDTs) Market

Recently, the problem has become more urgent due to the COVID-19 epidemic. Flu testing has increased dramatically across the US. Patients continue to report mixing up the flu with COVID-19 since both of these first symptoms are similar. However, the two viruses' sequential intervals and related fatality rates are different. Rapid influenza diagnostic testing has increased along with COVID-19 tests due to the epidemic.

Recent Development

• In April 2021, The acquisition of Luminex Corporation, a business involved in the development of diagnostic tools for infectious diseases, was announced by DiaSorin SpA. This acquisition aimed to increase the diagnostic goods available in the United States, including those for the diagnosis of influenza. This tactical choice helped the business grow its clientele and strengthen its position in the market.

Global Rapid Influenza Diagnostic Tests (RIDTs) Market Scope

The rapid influenza diagnostic tests (RIDTs) market is segmented on the basis of product, patient, type and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• RIDT for Influenza A
• RIDT for Influenza B

 Patient

• Pediatric
• Adult

End-use

• Hospitals
• Diagnostics Centers
• Research Laboratories

 Type

• Digital RIDTs
• Conventional RIDT

Rapid Influenza Diagnostic Tests (RIDTs) Market Regional Analysis/Insights

The rapid influenza diagnostic tests (RIDTs) market is analysed and market size insights and trends are provided by country, product, patient, type and end use as referenced above.

The countries covered in the rapid influenza diagnostic tests (RIDTs) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the rapid influenza diagnostic tests (RIDTs) market due to the high occurrences of influenza, rising hospitalisation, and growing patient population.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the growing geriatric population, rising health awareness among the people, and rising healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The rapid influenza diagnostic tests (RIDTs) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for rapid influenza diagnostic tests (RIDTs) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the rapid influenza diagnostic tests (RIDTs) market. The data is available for historic period 2010-2020.

Competitive Landscape and Rapid Influenza Diagnostic Tests (RIDTs) Market Share Analysis

The rapid influenza diagnostic tests (RIDTs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rapid influenza diagnostic tests (RIDTs) market.

Some of the major players operating in the rapid influenza diagnostic tests (RIDTs) market are:

• Siemens (Allemagne)
• Hologic, Inc. (États-Unis)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Chine)
• Abbott (États-Unis)
• BD (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Thermo Fisher Scientific Inc. (États-Unis)
• Koninklijke Philips NV (Pays-Bas)
• NeuroLogica Corp. (États-Unis)
• Shimadzu Medical (Inde) pvt. Ltd. (Japon)
• GENERAL ELECTRIC (ÉTATS-UNIS)
• Quest Diagnostics Incorporated (États-Unis)
• Sysmex Inde Pvt. Ltd. (Japon)
• Hitachi, Ltd. (Japon)
• Canon Inc. (Japon)
• FUJIFILM Holdings Corporation (Royaume-Uni)

SKU-54221